Analysts Set UroGen Pharma Ltd. (NASDAQ:URGN) PT at $43.70

UroGen Pharma Ltd. (NASDAQ:URGN - Get Free Report) has earned an average rating of "Buy" from the six ratings firms that are covering the stock, Marketbeat Ratings reports. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $43.70.

Several equities analysts recently commented on URGN shares. D. Boral Capital reaffirmed a "buy" rating and set a $25.00 target price on shares of UroGen Pharma in a report on Friday. EF Hutton Acquisition Co. I upgraded shares of UroGen Pharma to a "strong-buy" rating in a research report on Monday, October 14th. HC Wainwright reissued a "buy" rating and issued a $60.00 target price on shares of UroGen Pharma in a research note on Tuesday, October 15th. Oppenheimer restated an "outperform" rating and set a $40.00 price target on shares of UroGen Pharma in a research report on Wednesday, October 16th. Finally, Guggenheim assumed coverage on UroGen Pharma in a research note on Thursday, August 22nd. They issued a "buy" rating and a $40.00 price target on the stock.

Institutional Investors Weigh In On UroGen Pharma

Several institutional investors and hedge funds have recently modified their holdings of URGN. RTW Investments LP lifted its position in UroGen Pharma by 6.5% during the third quarter. RTW Investments LP now owns 3,787,347 shares of the company's stock valued at $48,099,000 after buying an additional 230,000 shares during the period. Great Point Partners LLC boosted its stake in UroGen Pharma by 10.9% in the 2nd quarter. Great Point Partners LLC now owns 2,906,259 shares of the company's stock worth $48,767,000 after purchasing an additional 285,714 shares in the last quarter. Point72 Asset Management L.P. grew its position in UroGen Pharma by 120.3% during the 2nd quarter. Point72 Asset Management L.P. now owns 2,449,277 shares of the company's stock valued at $41,099,000 after purchasing an additional 1,337,257 shares during the last quarter. Cowen AND Company LLC raised its holdings in UroGen Pharma by 29.1% in the second quarter. Cowen AND Company LLC now owns 2,099,482 shares of the company's stock worth $35,229,000 after buying an additional 472,893 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of UroGen Pharma by 1.6% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,341,072 shares of the company's stock worth $17,032,000 after buying an additional 21,072 shares in the last quarter. 91.29% of the stock is owned by hedge funds and other institutional investors.

UroGen Pharma Price Performance

URGN stock traded up $0.08 during mid-day trading on Friday, hitting $12.29. 309,244 shares of the stock were exchanged, compared to its average volume of 393,930. The company has a debt-to-equity ratio of 4.77, a current ratio of 9.00 and a quick ratio of 8.77. The stock has a market capitalization of $288.20 million, a price-to-earnings ratio of -3.90 and a beta of 1.06. The business has a fifty day moving average price of $12.28 and a 200 day moving average price of $13.96. UroGen Pharma has a 12 month low of $10.60 and a 12 month high of $20.70.

UroGen Pharma (NASDAQ:URGN - Get Free Report) last released its earnings results on Wednesday, November 6th. The company reported ($0.55) earnings per share for the quarter, topping analysts' consensus estimates of ($0.84) by $0.29. The firm had revenue of $25.20 million during the quarter, compared to the consensus estimate of $24.22 million. During the same quarter in the previous year, the firm earned ($0.68) EPS. On average, sell-side analysts anticipate that UroGen Pharma will post -3.1 EPS for the current year.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.